Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: | Stelara |
Active Ingredient: | Ustekinumab 45mg |
Dosage Form: | Solution for injection |
New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
Manufacturers: | Cilag AG, Schaffhausen, Switzerland Baxter Pharmaceutical Solutions LLC, Indiana, United States of America |
Product: | Stelara |
Active Ingredient: | Ustekinumab 90mg |
Dosage Form: | Solution for injection |
New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
Manufacturers: | Cilag AG, Schaffhausen, Switzerland Baxter Pharmaceutical Solutions LLC, Indiana, United States of America |
Product: | Stelara |
Active Ingredient: | Ustekinumab 130mg |
Dosage Form: | Concentrate for infusion |
New Zealand Sponsor: | Janssen-Cilag (New Zealand) Limited |
Manufacturer: | Cilag AG, Schaffhausen, Switzerland |
Dated this 6th day of December 2019.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).